Autolus Therapeutics PLC - American Depositary Shares (AUTL) closed at $1.55 on October 27, 2026, up 1.3% from the previous close, on volume of 1,734,870 shares (30-day average 1,611,290).
Data as of October 27, 2026.
27-Oct-2026
Globe Newswire (Mon, 26-Oct 4:15 PM ET)
Globe Newswire (Mon, 5-Oct 8:30 AM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
AUTL Raises FY26 Guidance as AUCATZYL Revenue Surges 119%—Gross Margins Hit 55% in Q2
Market Chameleon (Tue, 11-Aug 7:19 AM ET)
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Globe Newswire (Tue, 11-Aug 7:00 AM ET)
Globe Newswire (Mon, 3-Aug 4:05 PM ET)
Market Chameleon (Mon, 3-Aug 6:31 AM ET)
Globe Newswire (Mon, 3-Aug 7:13 AM ET)
Market Chameleon (Tue, 25-Nov 5:33 AM ET)
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.
As of October 27, 2026, AUTL stock price climbed to $1.55 with 1,734,870 million shares trading.
AUTL has a beta of 3.32, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.29 to the broad based SPY ETF.
AUTL has a market cap of $412.19 million. This is considered a Small Cap stock.
Last quarter Autolus Therapeutics PLC - American Depositary Shares reported $46 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.04.
In the last 3 years, AUTL traded as high as $7.45 and as low as $1.11.
The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, CANC, GWX, QQQS, APIE.
AUTL has underperformed the market in the last year with a price return of +1.3% while the SPY ETF gained +14.8%. However, in the short term, AUTL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.9% vs +4.4% return in SPY. But in the last 2 weeks, AUTL shares have been beat by the market, returning -10.9% compared to an SPY return of -1.1%.
AUTL support price is $1.47 and resistance is $1.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL shares will trade within this expected range on the day.
